Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26138078 | 0.93 | SLC22A6 (0.56) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL14399780 | 0.91 | SLC22A6 (0.48) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL13917736 | 0.89 | PDE4A (0.58) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL13917735 | 0.89 | PDE4A (0.58) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL769787 | 0.89 | PDE4A (0.58) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL28778990 | 0.88 | SLC22A6 (0.50) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL18586001 | 0.87 | TDP1 (0.60) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL4344384 | 0.87 | TDP1 (0.60) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL1650142 | 0.87 | TDP1 (0.60) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 | |
| SCHEMBL26138080 | 0.87 | PDE4A (0.62) | SLC22A6SMN1; SMN2LMNAGABRR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | claimed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | claimed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | claimed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | claimed |
| EP-1904489-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | Rib-X Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2006133397-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | Tipikos Pharmaceuticals, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | TOPIKOS PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| EP-1904489-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | Rib-X Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006133397-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234615-A1 | Process for the synthesis of triazoles | PROKR1, SI, IL33 | SLC22A6 4616/4885SMN1; SMN2 4672/4885LMNA 2397/4885 |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | SLC22A6 1842/4885SMN1; SMN2 3283/4885LMNA 4596/4885 |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | SLC22A6 1842/4885SMN1; SMN2 3283/4885LMNA 4596/4885 |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | PROKR1, VIP, SI | SLC22A6 4718/4885SMN1; SMN2 4365/4885LMNA 2527/4885 |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | SLC22A6 4616/4885SMN1; SMN2 4672/4885LMNA 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.